Literature DB >> 3024919

EBV-activation of human B-lymphocytes.

P Aman, N Lewin, M Nordström, G Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3024919     DOI： 10.1007/978-3-642-71562-4_40

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  6 in total

1.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells.

Authors:  D Liebowitz; J Mannick; K Takada; E Kieff
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.

Authors:  D Wang; D Liebowitz; F Wang; C Gregory; A Rickinson; R Larson; T Springer; E Kieff
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

3.  ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation.

Authors:  M W Hornef; G Bein; D Wilhelm; L Fricke; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A.

Authors:  W Lee; Y H Hwang; S K Lee; C Subramanian; E S Robertson
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin.

Authors:  D Liebowitz; E Kieff
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

Review 6.  Immune regulation in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows; D J Moss
Journal:  Microbiol Rev       Date:  1995-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.